2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

NCT03468335 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

151

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions

DRUG: Irinotecan Liposomal Injection [Onivyde]

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]
[object Object]